[144] Bicara Therapeutics Inc. SEC Filing

Rhea-AI Filing Summary

Bicara Therapeutics Inc. (BCAX) filed a Form 144 notifying a proposed sale of 39,600 common shares through UBS Financial Services on 10/06/2025 with an aggregate market value of $714,997.10. The filing shows two acquisition dates: 05/12/2024 for 15,600 shares from a nonqualified option exercise paid in cash, and 10/06/2025 for 24,000 shares from an NQSO also paid in cash. The total outstanding shares reported are 54,562,841, which places the proposed sale at roughly 0.07% of outstanding common stock. No sales by the reporting person in the prior three months were reported, and the filer states they are not aware of any undisclosed material adverse information.

Insights

Insider Transactions Analyst

Insider plans a small, disclosed sale that is routine for option exercise liquidity.

The notice shows a planned sale of 39,600 shares valued at $714,997.10, representing approximately 0.07% of the reported 54,562,841 outstanding shares. The shares were acquired via nonqualified option exercises on 05/12/2024 and 10/06/2025, with cash paid for both acquisitions.

This size of sale is immaterial to overall equity capitalization and is commonly used to cover tax and exercise costs. Monitor trading completion and any subsequent Form 4 disclosures within days after 10/06/2025 to confirm execution and exact proceeds.

Securities Compliance Counsel

Filing follows Rule 144 disclosure steps and includes the standard attestation.

The Form 144 lists broker details and includes the attestation that the seller knows of no undisclosed material adverse information. Acquisition and payment details (cash for NQ exercises) are provided, and there were no reported sales in the prior three months.

Compliance attention should focus on whether a trading plan (Rule 10b5-1) was used; the form allows indicating a plan adoption date but none is shown. Expect a Form 4 if sales occur; absence of a Form 4 within the required filing window could warrant follow-up.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc Eleven Madison Avenue 4th Floor New York NY 10010	39600	714997.10	54562841	10/06/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/12/2024	NQ Exercise shares	Issuer			15600	05/12/2024	Cash
Common	10/06/2025	NQSO	Issuer			24000	10/06/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)